Oncotelic Therapeutics (OTCQB: OTLC) announced the publication of a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma (“HCC”), a form of liver cancer. Published Oct. 23, 2026, the study used Partitioned Literature Aggregation (“PLA”), Oncotelic’s patented algorithm running on PDAOAI, alongside gene-expression and survival analyses to identify four genes: FKBP1A, EIF4E, RRAGC and PPARGC1A. The signature’s association with patient survival was independently validated in a Japanese HCC cohort of 203 patients. The findings support patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus.
Oncotelic Chief Business Officer Saran Saund presented the research approach during an Oct. 22 keynote at the 22nd Drug Discovery Strategic Summit in California. The company highlighted the potential of partitioned AI investigations to uncover testable biological hypotheses and advance drug discovery. Oncotelic plans to expand PDAOAI toward a target scale of approximately 100 billion biological vectors for genetic and protein research. Through its BIO REBOOT initiative, the company also invites researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning and clinical development, subject to scientific review and available resources.
To view the full press release, visit https://ibn.fm/ctJ4J
About Oncotelic
Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The Company also develops the PDAOAI platform to support its work in drug discovery and development.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN